- Home
- CELU vs PASG Comparison
CELU vs PASG Comparison
Compare CELU & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- PASG
- Stock Information
- Founded
- CELU 2016
- PASG 2017
- Country
- CELU United States
- PASG United States
- Employees
- CELU N/A
- PASG N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- PASG Health Care
- Exchange
- CELU Nasdaq
- PASG Nasdaq
- Market Cap
- CELU 37.7M
- PASG 31.1M
- IPO Year
- CELU N/A
- PASG 2020
- Fundamental
- Price
- CELU $2.11
- PASG $0.43
- Analyst Decision
- CELU
- PASG Strong Buy
- Analyst Count
- CELU 0
- PASG 3
- Target Price
- CELU N/A
- PASG $7.67
- AVG Volume (30 Days)
- CELU 91.2K
- PASG 376.9K
- Earning Date
- CELU 05-08-2025
- PASG 05-13-2025
- Dividend Yield
- CELU N/A
- PASG N/A
- EPS Growth
- CELU N/A
- PASG N/A
- EPS
- CELU N/A
- PASG N/A
- Revenue
- CELU $54,220,000.00
- PASG N/A
- Revenue This Year
- CELU $23.29
- PASG N/A
- Revenue Next Year
- CELU N/A
- PASG N/A
- P/E Ratio
- CELU N/A
- PASG N/A
- Revenue Growth
- CELU 138.11
- PASG N/A
- 52 Week Low
- CELU $1.00
- PASG $0.26
- 52 Week High
- CELU $5.22
- PASG $1.33
- Technical
- Relative Strength Index (RSI)
- CELU 54.10
- PASG 64.10
- Support Level
- CELU $1.90
- PASG $0.34
- Resistance Level
- CELU $2.47
- PASG $0.47
- Average True Range (ATR)
- CELU 0.29
- PASG 0.04
- MACD
- CELU 0.01
- PASG 0.02
- Stochastic Oscillator
- CELU 58.25
- PASG 84.55
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.